Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis

Joseph A. Digiuseppe, Patti Lebeau, Jeanne Augenbraun, Michael J Borowitz

Research output: Contribution to journalArticle

Abstract

Apoptosis (programmed cell death) is an important regulatory mechanism in hematopoiesis, and is thought to be a principal mechanism of action of cytotoxic chemotherapy. Proteins that modulate apoptosis include bcl-2, which inhibits apoptosis, and Fas (CD95, also known as APO-1), which induces apoptosis in susceptible cells bound by Fas ligand (FasL). To characterize precisely the expression of these apoptosis-regulatory proteins in normal and neoplastic hematopoiesis, the authors have performed multiparameter flow cytometric (FCM) analysis in a series of normal and abnormal marrow specimens. Among normal hematopoietic elements, bcl-2 expression was highest in myeloblasts (29 [± 9] x 103 molecules of equivalent soluble fluorochrome [MESF]), and lymphocytes (28 [± 7] x 103 MESF). bcl-2 was essentially undetectable in granulocytes and nucleated red blood cells, whereas monocytes and B-cell precursors expressed intermediate levels of bcl-2 (11 [± 4] x 103 and 7 [± 1] x 103 MESF, respectively), Fas expression increased with granulocytic and monocytic differentiation; myeloblasts expressed 8 (± 2) x 103 MESF, whereas granulocytes (15 [± 2] x 103 MESF) and monocytes (28 [± 5] x 103 MESF) displayed relatively greater intensity of staining for Fas. Among lymphoid cells, Fas expression was heterogeneous. B cells expressed lower intensity Fas staining than both CD4+ and CD8+ T cells. Myeloblasts in 30 cases of myeloid leukemia and myelodysplasia studied for bcl-2 and/or Fas expression manifested variable levels of these molecules (range 9-105 x 103 MESF for bcl-2 and 3-33 x 103 MESF for Fas). In addition, intraclonal heterogeneity of bcl-2 and Fas expression was seen in certain cases of AML, which correlated with extent of differentiation. Among 28 cases of B- precursor ALL studied for bcl-2 and/or Fas expression, bcl-2 ranged from 22 to 60 x 103 MESF (P 3 MESF. In summary, normal marrow subsets display characteristic levels of the apoptosis- regulatory molecules, bcl-2 and Fas. In hematopoietic neoplasms, expression of bcl-2 and Fas varies among cases, and in some instances, within leukemic blast populations. Further study is required to understand the potential significance of this heterogeneous expression of bcl-2 and Fas in hematologic neoplasia.

Original languageEnglish (US)
Pages (from-to)345-351
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume106
Issue number3
StatePublished - Sep 1996

Fingerprint

Hematopoiesis
Fluorescent Dyes
Granulocyte Precursor Cells
Apoptosis
Granulocytes
Monocytes
Bone Marrow
Lymphocytes
Staining and Labeling
Apoptosis Regulatory Proteins
Myeloid Leukemia
Fas Ligand Protein
B-Lymphoid Precursor Cells
Hematologic Neoplasms
B-Lymphocytes
Cell Death
Erythrocytes
T-Lymphocytes
Drug Therapy

Keywords

  • Apoptosis
  • bcl-2
  • Fas
  • Leukemia
  • Myelopoiesis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis. / Digiuseppe, Joseph A.; Lebeau, Patti; Augenbraun, Jeanne; Borowitz, Michael J.

In: American Journal of Clinical Pathology, Vol. 106, No. 3, 09.1996, p. 345-351.

Research output: Contribution to journalArticle

@article{2967d22996d041fba08d7a523e80796e,
title = "Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis",
abstract = "Apoptosis (programmed cell death) is an important regulatory mechanism in hematopoiesis, and is thought to be a principal mechanism of action of cytotoxic chemotherapy. Proteins that modulate apoptosis include bcl-2, which inhibits apoptosis, and Fas (CD95, also known as APO-1), which induces apoptosis in susceptible cells bound by Fas ligand (FasL). To characterize precisely the expression of these apoptosis-regulatory proteins in normal and neoplastic hematopoiesis, the authors have performed multiparameter flow cytometric (FCM) analysis in a series of normal and abnormal marrow specimens. Among normal hematopoietic elements, bcl-2 expression was highest in myeloblasts (29 [± 9] x 103 molecules of equivalent soluble fluorochrome [MESF]), and lymphocytes (28 [± 7] x 103 MESF). bcl-2 was essentially undetectable in granulocytes and nucleated red blood cells, whereas monocytes and B-cell precursors expressed intermediate levels of bcl-2 (11 [± 4] x 103 and 7 [± 1] x 103 MESF, respectively), Fas expression increased with granulocytic and monocytic differentiation; myeloblasts expressed 8 (± 2) x 103 MESF, whereas granulocytes (15 [± 2] x 103 MESF) and monocytes (28 [± 5] x 103 MESF) displayed relatively greater intensity of staining for Fas. Among lymphoid cells, Fas expression was heterogeneous. B cells expressed lower intensity Fas staining than both CD4+ and CD8+ T cells. Myeloblasts in 30 cases of myeloid leukemia and myelodysplasia studied for bcl-2 and/or Fas expression manifested variable levels of these molecules (range 9-105 x 103 MESF for bcl-2 and 3-33 x 103 MESF for Fas). In addition, intraclonal heterogeneity of bcl-2 and Fas expression was seen in certain cases of AML, which correlated with extent of differentiation. Among 28 cases of B- precursor ALL studied for bcl-2 and/or Fas expression, bcl-2 ranged from 22 to 60 x 103 MESF (P 3 MESF. In summary, normal marrow subsets display characteristic levels of the apoptosis- regulatory molecules, bcl-2 and Fas. In hematopoietic neoplasms, expression of bcl-2 and Fas varies among cases, and in some instances, within leukemic blast populations. Further study is required to understand the potential significance of this heterogeneous expression of bcl-2 and Fas in hematologic neoplasia.",
keywords = "Apoptosis, bcl-2, Fas, Leukemia, Myelopoiesis",
author = "Digiuseppe, {Joseph A.} and Patti Lebeau and Jeanne Augenbraun and Borowitz, {Michael J}",
year = "1996",
month = "9",
language = "English (US)",
volume = "106",
pages = "345--351",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis

AU - Digiuseppe, Joseph A.

AU - Lebeau, Patti

AU - Augenbraun, Jeanne

AU - Borowitz, Michael J

PY - 1996/9

Y1 - 1996/9

N2 - Apoptosis (programmed cell death) is an important regulatory mechanism in hematopoiesis, and is thought to be a principal mechanism of action of cytotoxic chemotherapy. Proteins that modulate apoptosis include bcl-2, which inhibits apoptosis, and Fas (CD95, also known as APO-1), which induces apoptosis in susceptible cells bound by Fas ligand (FasL). To characterize precisely the expression of these apoptosis-regulatory proteins in normal and neoplastic hematopoiesis, the authors have performed multiparameter flow cytometric (FCM) analysis in a series of normal and abnormal marrow specimens. Among normal hematopoietic elements, bcl-2 expression was highest in myeloblasts (29 [± 9] x 103 molecules of equivalent soluble fluorochrome [MESF]), and lymphocytes (28 [± 7] x 103 MESF). bcl-2 was essentially undetectable in granulocytes and nucleated red blood cells, whereas monocytes and B-cell precursors expressed intermediate levels of bcl-2 (11 [± 4] x 103 and 7 [± 1] x 103 MESF, respectively), Fas expression increased with granulocytic and monocytic differentiation; myeloblasts expressed 8 (± 2) x 103 MESF, whereas granulocytes (15 [± 2] x 103 MESF) and monocytes (28 [± 5] x 103 MESF) displayed relatively greater intensity of staining for Fas. Among lymphoid cells, Fas expression was heterogeneous. B cells expressed lower intensity Fas staining than both CD4+ and CD8+ T cells. Myeloblasts in 30 cases of myeloid leukemia and myelodysplasia studied for bcl-2 and/or Fas expression manifested variable levels of these molecules (range 9-105 x 103 MESF for bcl-2 and 3-33 x 103 MESF for Fas). In addition, intraclonal heterogeneity of bcl-2 and Fas expression was seen in certain cases of AML, which correlated with extent of differentiation. Among 28 cases of B- precursor ALL studied for bcl-2 and/or Fas expression, bcl-2 ranged from 22 to 60 x 103 MESF (P 3 MESF. In summary, normal marrow subsets display characteristic levels of the apoptosis- regulatory molecules, bcl-2 and Fas. In hematopoietic neoplasms, expression of bcl-2 and Fas varies among cases, and in some instances, within leukemic blast populations. Further study is required to understand the potential significance of this heterogeneous expression of bcl-2 and Fas in hematologic neoplasia.

AB - Apoptosis (programmed cell death) is an important regulatory mechanism in hematopoiesis, and is thought to be a principal mechanism of action of cytotoxic chemotherapy. Proteins that modulate apoptosis include bcl-2, which inhibits apoptosis, and Fas (CD95, also known as APO-1), which induces apoptosis in susceptible cells bound by Fas ligand (FasL). To characterize precisely the expression of these apoptosis-regulatory proteins in normal and neoplastic hematopoiesis, the authors have performed multiparameter flow cytometric (FCM) analysis in a series of normal and abnormal marrow specimens. Among normal hematopoietic elements, bcl-2 expression was highest in myeloblasts (29 [± 9] x 103 molecules of equivalent soluble fluorochrome [MESF]), and lymphocytes (28 [± 7] x 103 MESF). bcl-2 was essentially undetectable in granulocytes and nucleated red blood cells, whereas monocytes and B-cell precursors expressed intermediate levels of bcl-2 (11 [± 4] x 103 and 7 [± 1] x 103 MESF, respectively), Fas expression increased with granulocytic and monocytic differentiation; myeloblasts expressed 8 (± 2) x 103 MESF, whereas granulocytes (15 [± 2] x 103 MESF) and monocytes (28 [± 5] x 103 MESF) displayed relatively greater intensity of staining for Fas. Among lymphoid cells, Fas expression was heterogeneous. B cells expressed lower intensity Fas staining than both CD4+ and CD8+ T cells. Myeloblasts in 30 cases of myeloid leukemia and myelodysplasia studied for bcl-2 and/or Fas expression manifested variable levels of these molecules (range 9-105 x 103 MESF for bcl-2 and 3-33 x 103 MESF for Fas). In addition, intraclonal heterogeneity of bcl-2 and Fas expression was seen in certain cases of AML, which correlated with extent of differentiation. Among 28 cases of B- precursor ALL studied for bcl-2 and/or Fas expression, bcl-2 ranged from 22 to 60 x 103 MESF (P 3 MESF. In summary, normal marrow subsets display characteristic levels of the apoptosis- regulatory molecules, bcl-2 and Fas. In hematopoietic neoplasms, expression of bcl-2 and Fas varies among cases, and in some instances, within leukemic blast populations. Further study is required to understand the potential significance of this heterogeneous expression of bcl-2 and Fas in hematologic neoplasia.

KW - Apoptosis

KW - bcl-2

KW - Fas

KW - Leukemia

KW - Myelopoiesis

UR - http://www.scopus.com/inward/record.url?scp=0029782377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029782377&partnerID=8YFLogxK

M3 - Article

C2 - 8816592

AN - SCOPUS:0029782377

VL - 106

SP - 345

EP - 351

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -